Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a simple oxygen change help ICU patients breathe easier after tube removal?

NCT ID NCT05904652

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving high-flow oxygen through the nose just before removing a breathing tube is safe and acceptable for patients in intensive care with severe breathing problems. Only 2 patients took part, and the main goal was to see if a larger study is possible. The researchers compared this new approach to standard low-flow oxygen given after tube removal.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
High flow nasal oxygen delivery device
What this could lead to
If successful, this could lead to a larger trial testing whether high-flow oxygen before tube removal reduces the need for re-intubation.
What could go wrong
This is a very small feasibility study with only 2 participants, so results are not generalizable. It is designed to test recruitment and safety, not effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2 people

The number who actually took part.

Started

Sep 2023

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant aged 18 to 80 years old at time of recruitment to study) * Ventilated for greater than or equal to 48 hours with respiratory failure * Treating clinician agrees ready for a planned extubation (but pressure support ventilation, fraction of inspired oxygen less than or equal to 40 , positive end expiratory pressure less than or equal to 10 centimetres of water, Respiratory rate less than 20 breaths per minute) * Minimal secretions * Neurologically intact (In the opinion of the treating clinician, the participant is unlikely to fail extubation due to their neurological status) * Cardiovascularly stable (systolic blood pressure greater than or equal to 70 millimetres of mercury, heart rate less than or equal to 150 beats per minute) * Written informed consent Exclusion Criteria: * Cardiac Implant Device * Internal Neurostimulator * Unstable Spinal Fracture or Spinal Cord Injury * Body Mass Index \>50kg/m\^2 * Skin lesions or dressings over electrode belt site * Pregnancy or Lactating * Intercostal Chest Drain (at treating clinician's discretion) * Severe type II respiratory failure (arterial partial pressure of carbon dioxide greater than or equal to 12 kilopascals) * Severe acidosis (Hydrogen ion concentration greater than or equal to 80 nanomoles per litre) * Chronic respiratory disease limiting functional capacity (MRC breathlessness grade IV or V) * Severe heart failure (New York Heart Association Grade III or IV) * Decreased GCS * Cardiovascular instability (systolic blood pressure less than or equal to 69 millimetres of mercury or heart rate greater than or equal to 151 millimetres of mercury ) * Pulmonary embolism * Nasal obstruction * Previous bleomycin administration * Base of skull fracture * Life expectancy less than or equal to 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Critical Care Medicine, Queen Elizabeth University Hospital

    Glasgow, Scotland, G51 4TF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.